Coeptis Therapeutics Holdings, Inc. (COEP)
Industry: Biotechnology

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Current Quote*
Last: $3.730
Change: 0.000
Book: $13.333
Volume: 490,288

As Of: 09/25 16:06 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol COEP

Graphs for COEP


3 Month Graph


6 Month Graph


1 Year Graph